InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard EPS

- January 23rd, 2019

InspireMD (NYSE:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard EPS were presented at LINC 2019, which is being held January 21 – 23 in Leipzig, Germany. As quoted in the press release: … Continued

InspireMD (NYSE:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard EPS were presented at LINC 2019, which is being held January 21 – 23 in Leipzig, Germany.

As quoted in the press release:

The first live case was conducted by Dr. Antonio Micari and Dr. Fausto Castriota, interventional cardiologists at Humanitas Gavazzeni Hospital, Bergamo, Italy. The patient had stable angina over the prior twelve months, with one hospital admission for one transient ischemic attack (TIA) approximately one month ago. The risk factors included hypertension, hypercholesterolemia and critical left interior carotid artery (LICA) stenosis with evidence of soft plaque. The procedure was successfully performed  with the 8mm x 40mm CGuard™ EPS, lasted approximately 20 minutes and had an excellent angiographic result.

Following the procedure, Drs. Micari and Castriota commented, “This patient presented with multiple co-morbidities, including a history of transient ischemic attacks, and a large amount of soft plaque that significantly increases the chance of embolization associated with conventional carotid stents. There were no adverse events during the procedure. At this early stage, it appears that CGuard™ EPS offers superior patient protection where conventional carotid stents may not.”

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Leave a Reply

Your email address will not be published. Required fields are marked *